1. Home
  2. BSL vs NYXH Comparison

BSL vs NYXH Comparison

Compare BSL & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone

BSL

Blackstone

HOLD

Current Price

$13.51

Market Cap

176.1M

Sector

Finance

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$4.66

Market Cap

188.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BSL
NYXH
Founded
2010
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
176.1M
188.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
BSL
NYXH
Price
$13.51
$4.66
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$12.67
AVG Volume (30 Days)
71.9K
29.4K
Earning Date
01-01-0001
11-13-2025
Dividend Yield
9.55%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$6,616,215.00
Revenue This Year
N/A
$75.27
Revenue Next Year
N/A
$277.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
10.96
52 Week Low
$12.19
$4.35
52 Week High
$14.56
$11.87

Technical Indicators

Market Signals
Indicator
BSL
NYXH
Relative Strength Index (RSI) 39.54 49.30
Support Level $13.50 $4.45
Resistance Level $13.59 $4.86
Average True Range (ATR) 0.08 0.21
MACD -0.00 0.00
Stochastic Oscillator 29.31 60.42

Price Performance

Historical Comparison
BSL
NYXH

About BSL Blackstone

Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It also invests in second-lien loans and high yield bonds and employs financial leverage which may increase the risk to the Fund.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: